TY - JOUR
T1 - Single-Cell Genomics Details the Maturation Block in BCP-ALL and Identifies Therapeutic Vulnerabilities in DUX4-Rearranged Cases
AU - Thorsson, Hanna
AU - Henningsson, Rasmus
AU - Puente-moncada, Noelia
AU - Sjöström, Ludvig
AU - Ågerstam, Helena
AU - Peña-martínez, Pablo Enrique
AU - Sandén, Carl
AU - Rissler, Marianne
AU - Castor, Anders
AU - Marquart, Hanne Vibeke
AU - Modvig, Signe
AU - Paulsson, Kajsa
AU - Pronk, Cornelis
AU - Schmiegelow, Kjeld
AU - Hyrenius Wittsten, Axel
AU - Orsmark-pietras, Christina
AU - Lilljebjörn, Henrik Phd
AU - Fioretos, Thoas
PY - 2023
Y1 - 2023
N2 - B cell progenitor acute lymphoblastic leukemia (BCP-ALL) is the most common childhood malignancy. It is initiated by multiple genetic alterations, causing a maturation arrest and accumulation of abnormal progenitor B cells. Current treatment protocols with chemotherapy have led to favorable outcomes, but are associated with significant toxicity and risk of side effects, highlighting the necessity for highly effective, less toxic, targeted drugs that also show efficacy in children experiencing relapse.
AB - B cell progenitor acute lymphoblastic leukemia (BCP-ALL) is the most common childhood malignancy. It is initiated by multiple genetic alterations, causing a maturation arrest and accumulation of abnormal progenitor B cells. Current treatment protocols with chemotherapy have led to favorable outcomes, but are associated with significant toxicity and risk of side effects, highlighting the necessity for highly effective, less toxic, targeted drugs that also show efficacy in children experiencing relapse.
U2 - 10.1182/blood-2023-173350
DO - 10.1182/blood-2023-173350
M3 - Journal article
VL - 142
SP - 842
JO - Blood
JF - Blood
SN - 0006-4971
IS - Supplement 1
ER -